Business Wire

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only ...
Morningstar

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic ...
Pharmabiz

US FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx, a companion diagnostic indicated to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Agilent Technologies Inc., a global leader in analytical and clinical laboratory technologies, announced that the US Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, ...